Based on this understanding, cancer vaccines and immune checkpoint therapies are being created to attack immunogenic tumors that produce antigenic peptides to naive CD8+ T cells, whereas transfection of genetically modified T cell treatment can identify tumor cell-derived surface proteins that directly have evolved to target non-immunogenic tumors [7]. This evidence concerns the gene CD8A and cancer.